Biological
ALVAC-HIV
ALVAC-HIV is a biological therapy with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Phase Distribution
Ph phase_2
2
50%
Ph phase_1
2
50%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Other(2)
Detailed Status
unknown2
Completed2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (50.0%)
Phase 22 (50.0%)
Trials by Status
unknown250%
completed250%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_1
A Safety and Immune Response Study of 2 Experimental HIV Vaccines
NCT02404311
unknownphase_2
Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/E
NCT01931358
unknownphase_2
Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144
NCT01435135
completedphase_1
Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy Adults
NCT02109354
Clinical Trials (4)
Showing 4 of 4 trials
NCT02404311Phase 1
A Safety and Immune Response Study of 2 Experimental HIV Vaccines
NCT01931358Phase 2
Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/E
NCT01435135Phase 2
Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144
NCT02109354Phase 1
Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy Adults
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4